Want to see UTHR full AI Analyst Report?
UTHR Stock Chart & Stats
$516.68
-$0.53(-0.10%)
At close: 4:00 PM EDT
$516.68
-$0.53(-0.10%)
Day’s Range― - ―
52-Week Range$375.61 - $609.35
Previous Close$527.94
Volume431.35K
Average Volume (3M)495.91K
Market Cap
$21.10B
Enterprise Value$22.15K
Total Cash (Recent Filing)$2.66B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)16.2
Beta0.55
Next Earnings
Nov 04, 2026EPS Estimate
6.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)30.23
Shares Outstanding42,890,694
10 Day Avg. Volume441,853
30 Day Avg. Volume495,906
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)3.04
Price to Sales (P/S)6.78
P/FCF Ratio20.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$655.13Price Target Upside26.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)26.15
Revenue Forecast (FY)$3.15B
Bulls Say, Bears Say
Bulls Say
High Profitability And Cash GenerationExceptional margins and substantial operating and free cash flow show that the PAH franchise converts demand into durable earnings and internal funding. This supports continued investment in clinical programs, manufacturing capacity and commercial expansion without relying heavily on external capital.
Debt-Free Balance SheetEssentially zero leverage gives United Therapeutics significant financial flexibility to absorb development risk, fund organ-manufacturing initiatives and pursue growth opportunities. The strong equity base and returns profile also reduce dependence on debt markets during uncertain operating periods.
Expanding Clinical And Organ PipelineThe company is building growth options beyond its established PAH products through late-stage pulmonary fibrosis programs, ralinepag and xenotransplantation. Positive clinical results, regulatory submissions and full PPF enrollment could broaden the addressable market over the next several years.
Bears Say
Sharp TTM Revenue ContractionA steep decline in reported revenue introduces uncertainty about the durability of the current earnings base and the timing of recovery. Even with strong margins, sustained contraction could constrain operating leverage, reduce visibility and increase reliance on future pipeline launches.
Tyvaso Competitive And Concentration RiskTyvaso remains the company’s largest revenue driver, so competitive share pressure in inhaled prostacyclin therapies could materially affect growth and cash generation. Patient metrics remain strong, but revenue concentration leaves results exposed until newer products diversify the franchise.
Revenue And Regulatory Execution UncertaintyThe absence of reaffirmed guidance signals limited visibility while commercial trends, launch logistics and regulatory decisions develop. Delays or an unfavorable review timeline for key filings could postpone diversification and extend pressure on the existing product franchise.
United Therapeutics News
UTHR FAQ
What was United Therapeutics’s price range in the past 12 months?
United Therapeutics lowest stock price was $375.61 and its highest was $609.35 in the past 12 months.
What is United Therapeutics’s market cap?
United Therapeutics’s market cap is $21.10B.
When is United Therapeutics’s upcoming earnings report date?
United Therapeutics’s upcoming earnings report date is Nov 04, 2026 which is in 61 days.
How were United Therapeutics’s earnings last quarter?
United Therapeutics released its earnings results on Aug 05, 2026. The company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.862 by $0.408.
Is United Therapeutics overvalued?
According to Wall Street analysts United Therapeutics’s price is currently Undervalued.
Does United Therapeutics pay dividends?
United Therapeutics does not currently pay dividends.
What is United Therapeutics’s EPS estimate?
United Therapeutics’s EPS estimate is 6.44.
How many shares outstanding does United Therapeutics have?
United Therapeutics has 42,890,694 shares outstanding.
What happened to United Therapeutics’s price movement after its last earnings report?
United Therapeutics reported an EPS of $7.27 in its last earnings report, beating expectations of $6.862. Following the earnings report the stock price went up 0.064%.
Which hedge fund is a major shareholder of United Therapeutics?
Currently, no hedge funds are holding shares in UTHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
United Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$655.13 (26.80% Upside)
$655.13 (26.80% Upside)
Blogger Sentiment
Neutral
UTHR Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 45.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
25.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.70%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
United Therapeutics
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
UTHR Company Deck
UTHR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced significant near-term commercial challenges with very strong clinical and pipeline momentum. Short-term results (Q2 revenue) came in below expectations and Tyvaso faces competitive pressure, creating uncertainty for 2026 revenue. Offsetting this are multiple highly positive Phase III outcomes, major regulatory filings (ralinepag NDA and Tyvaso IPF sNDA), planned additional filings (DPI and SMI), near-complete enrollment for a large PPF trial, aggressive commercial investments (≈100% sales force expansion), and progress across a differentiated xenotransplantation/organ pipeline. Given the material potential of the recent clinical wins and the company’s execution initiatives that could drive meaningful upside in 2027 and beyond, the positives outweigh the near-term lowlights.View all UTHR earnings summariesUTHR Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
UTHR Stock 12 Month Forecast
Average Price Target
$655.13
▲(26.80% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Insmed
―
Jazz Pharmaceuticals
―
BridgeBio Pharma
―
Ownership Overview
1.95% Insiders
23.10% Mutual Funds
24.43% Other Institutional Investors
19.08% Public Companies and Individual Investors